



## PRESS RELEASE

### **Accuro Biologics Ltd and MilleGen SA enter into a collaborative agreement**

**ABERDEEN, UK — 16 May, 2008 — Accuro Biologics Ltd**, a privately held biotechnology services company specialising in advanced protein engineering technologies, expression clone development and immunogenicity (T cell epitope) evaluation studies, and **MilleGen SA**, a biotech company focused on Directed Molecular Evolution (DME) and committed to the research and development of human therapeutic antibodies announced today that they have entered into a strategic collaboration. The agreement brings together MilleGen's DME platform MutaGen™ and Accuro Biologics know-how and expert capabilities in antibody engineering and T cell epitope identification. The collaboration will allow the generation of a new and innovative platform directed towards the development of therapeutic antibody candidates with superior and significantly enhanced properties.

Graham Carter, Managing Director of Accuro Biologics commented, "We are very pleased to work with MilleGen in the provision of advanced antibody optimisation technologies. This agreement enhances the existing core competences of the two companies and provides our clients the opportunity to access strong and innovative technologies for therapeutic antibody optimisation."

"The track record and excellent antibody and protein engineering capabilities of Accuro Biologics make them an ideal partner to complement the innovative technologies already provided by MilleGen. This collaboration will result in humanised antibodies fully optimised with respect to their affinity, specificity and immunogenicity risk profile in a single step," said Dr. Philippe Mondon Chief Technology Officer, MilleGen SA.



### **About Accuro Biologics Ltd**

Accuro Biologics is a specialist research services company to the pharmaceutical, biotechnology and wider research community. The company provides a suite of advanced capabilities in protein and antibody engineering, expression clone development and immunogenicity (T cell epitope) evaluation. Founded on a significant industry track record, the company delivers highly cost effective services with added value provided by adherence to time lines, budget and high quality science. The company is UK-based and operates from its own fully equipped laboratories within the Aberdeen Science and Technology Park, Aberdeen, Scotland.

For more information, visit:  
[www.accurobio.com](http://www.accurobio.com)



### **About MilleGen SA**

MilleGen is a biotech company focused on Directed Molecular Evolution (DME) and committed to the research and development of human therapeutic antibodies. MilleGen, founded in 1999 and based in Toulouse, France, has developed and patented a powerful DME method (MutaGen™) to generate molecular diversity that can be applied to any protein-based products. MutaGen™ protein optimization technology occupies the heart of an efficient platform dedicated to the antibody discovery and improvement. This platform allows discovery of antibody candidates from human monoclonal antibody libraries and their optimization into a highly potent product and the expression of a whole human antibody molecule ready to enter preclinical development.

For more information, visit:  
[www.millegen.com](http://www.millegen.com)

### **For further information contact:**

Graham Carter  
Managing Director  
Accuro Biologics Ltd  
Crombie Lodge  
Aberdeen Science Park  
Balgownie Drive  
Aberdeen AB22 8GU  
UK

Tel: +44 (0) 1224 707337  
Email: [graham.carter@accurobio.com](mailto:graham.carter@accurobio.com)

Anne Deflisque  
Business Development Manager  
MilleGen  
Immeuble BIOSTEP. Bât. A  
Rue Pierre et Marie Curie  
BP 38183  
31681 LABEGE cedex  
France

Tel: +33 (0)5 61 28 70 10  
Email: [anne.deflisque@millegen.com](mailto:anne.deflisque@millegen.com)